ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2553

Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database

H Yu, K Angelini, A Dominique and TA Simon, Bristol-Myers Squibb, Princeton, NJ

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Abatacept, drug safety, drug safety monitoring and pregnancy

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Women are affected by RA 3–4 times more often than men. RA treatment choice during pregnancy can be a challenge for women to minimize fetal toxicity while maintaining disease control. The new FDA ‘Pregnancy and Lactation Labeling Rule’ removed pregnancy categories requiring product labels to be updated.1 Given limited information, it is important to continually assess available data on RA therapy use during pregnancy.

Methods: All pregnancy cases reported to the manufacturer were re-coded based on ICH E2B (R2) Guideline2 and MedDRA Points to Consider.3 A comprehensive, post-coding change evaluation of pregnancy cases from available sources was performed cumulatively up to March 31, 2016.

Results: In total, 356 cases were reported: clinical trials (114), spontaneous/literature (133), patient support programs/Phase IV trials (89), and Organization of Teratology Information Specialists Pregnancy Register (20). Most abatacept exposure was limited to the first trimester (118). Outcomes were reported in 196 cases (Table 1): 48% normal newborn/live births (4 full-term abatacept exposure cases), 21% spontaneous abortions, 9% live births with complications including premature delivery and low birth weight. There were 10 congenital anomalies in patients with multiple risk factors4 (2 full-term abatacept exposure cases, Table 2).

Conclusion: As shown, reports of spontaneous abortion, premature delivery, and low birth weight among patients treated with abatacept are low and consistent with the literature.5–8 The available data do not suggest an increased risk of adverse pregnancy outcomes with abatacept in the indicated population. However, abatacept should be used during pregnancy only if the benefit to the mother justifies potential risk to the fetus.9 The outcomes of abatacept-exposed pregnancies will continue to be monitored via pharmacovigilance and the Pregnancy Registry.   1.    FDA. Pregnancy and Lactation Labeling Final Rule. http://goo.gl/5CDV82. Accessed 6-2-2016. 2.    ICH E2B (R2) Guideline. http://goo.gl/L5GQwK. Accessed 6-7-2016. 3.    MedDRA. Points to Consider Release 4.11 Based on MedDRA Version 19.0. http://goo.gl/WJsF4x. Accessed 6-7-2016. 4.    Krause ML, et al. Ther Adv Musculoskelet Dis 2014;6:169–84. 5.    de Man YA, et al. Arthritis Rheum 2009;60:3196–206. 6.    Bowden AP, et al. J Rheumatol 2001;28:355–9. 7.    Rom AL, et al. Arthritis Rheumatol 2014;66:3265–73. 8.    Wallenius M, et al. J Rheumatol 2015;42:1570–2. 9.    Bristol-Myers Squibb. US Orencia Prescribing Information. http://packageinserts.bms.com/pi/pi_orencia.pdf. Accessed 6-2-2016.  

 

Disclosure: H. Yu, Bristol-Myers Squibb, 3; K. Angelini, Bristol-Myers Squibb, 1,Bristol-Myers Squibb, 3; A. Dominique, Bristol-Myers Squibb, 1,Bristol-Myers Squibb, 3; T. Simon, Bristol-Myers Squibb, 1,Bristol-Myers Squibb, 3.

To cite this abstract in AMA style:

Yu H, Angelini K, Dominique A, Simon T. Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/pregnancy-outcomes-in-patients-with-rheumatoid-arthritis-treated-with-abatacept-review-of-a-safety-database/. Accessed December 7, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcomes-in-patients-with-rheumatoid-arthritis-treated-with-abatacept-review-of-a-safety-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.